Sarepta Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
SRPT$16.42-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share data)
| For the Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenues: | |||
| Products, net | $1,144,876 | $843,769 | $612,401 |
| Collaboration and other | 98,460 | 89,244 | 89,486 |
| Total revenues | 1,243,336 | 933,013 | 701,887 |
| Cost and expenses: | |||
| Cost of sales (excluding amortization of in-licensed rights) | 150,343 | 139,989 | 97,049 |
| Research and development | 877,387 | 877,090 | 771,182 |
| Selling, general and administrative | 481,871 | 451,421 | 282,660 |
| Settlement and license charges | — | — | 10,000 |
| Amortization of in-licensed rights | 1,559 | 714 | 706 |
| Total cost and expenses | 1,511,160 | 1,469,214 | 1,161,597 |
| Operating loss | (267,824) | (536,201) | (459,710) |
| Other (loss) income, net: | |||
| Loss on debt extinguishment | (387,329) | (125,441) | — |
| Gain from sale of Priority Review Voucher | 102,000 | — | 102,000 |
| Other income (expense), net | 33,055 | (28,321) | (61,238) |
| Total other (loss) income, net | (252,274) | (153,762) | 40,762 |
| Loss before income tax expense (benefit) | (520,098) | (689,963) | (418,948) |
| Income tax expense (benefit) | 15,879 | 13,525 | (168) |
| Net loss | $(535,977) | $(703,488) | $(418,780) |
| Other comprehensive income (loss): | |||
| Unrealized gains (losses) on investments, net of tax | $2,582 | $(1,644) | $(23) |
| Total other comprehensive income (loss) | 2,582 | (1,644) | (23) |
| Comprehensive loss | $(533,395) | $(705,132) | $(418,803) |
| Net loss per share — basic and diluted | $(5.80) | $(8.03) | $(5.15) |
| Weighted-average number of shares of common stock used in computing basic and diluted net loss per share | 92,398 | 87,559 | 81,262 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.